Although investigators have observed the expression of CSC markers to vary depending on experimental conditions and tumor type, ALDH has been consistently identified as a CSC marker in breast cancer and prostate cancer, and levels of ALDHbright cells have been observed to predict worse oncologic outcome in numerous human cancers, including soft tissue sarcoma (STS) [7, 13–18]. Here, LDHA is linked to telomere syndrome.